Our Work
Latham & Watkins Advises Ro in Its US$150 Million Funding Round
February 16, 2022
An emerging companies deal team advises on the financing that will accelerate integration of the company’s services into a unified patient experience.
Ro, the direct-to-patient healthcare company, has announced it has raised an additional US$150 million exclusively from existing investors.
Latham & Watkins LLP represents Ro in the financing with an emerging companies deal team led by New York partner Peyton Worley, with New York associates Evan Kirsch and Mikhail Bushinski.